179 related articles for article (PubMed ID: 27941767)
1. MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.
Pourhassan H; DeFor T; Trottier B; Dolan M; Brunstein C; Bejanyan N; Ustun C; Warlick ED
Bone Marrow Transplant; 2017 Apr; 52(4):532-538. PubMed ID: 27941767
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
3. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy.
Konuma T; Itonaga H; Shimomura Y; Fujioka M; Aoki K; Uchida N; Onizuka M; Jinguji A; Tanaka M; Ueda Y; Katayama Y; Sawa M; Tanaka H; Nakamae H; Kawakita T; Maruyama Y; Takahashi S; Ishimaru F; Kanda J; Ichinohe T; Atsuta Y
Hematol Oncol; 2024 Jan; 42(1):e3217. PubMed ID: 37592904
[TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.
Majhail NS; Brunstein CG; Shanley R; Sandhu K; McClune B; Oran B; Warlick ED; Wagner JE; Weisdorf DJ
Bone Marrow Transplant; 2012 Apr; 47(4):494-8. PubMed ID: 21602900
[TBL] [Abstract][Full Text] [Related]
5. Comparison of unrelated cord blood and peripheral blood stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity conditioning regimen: a collaborative study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party.
Robin M; Ruggeri A; Labopin M; Niederwieser D; Tabrizi R; Sanz G; Bourhis JH; van Biezen A; Koenecke C; Blaise D; Tischer J; Craddock C; Maillard N; Mohty M; Russel N; Schetelig J; Finke J; Gluckman E; de Witte TM; Rocha V; Kroger N
Biol Blood Marrow Transplant; 2015 Mar; 21(3):489-95. PubMed ID: 25529382
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil.
Tavares RCB; Bonfim CS; Seber A; Pereira Lermontov S; Coulturato V; Zecchin VG; Ribeiro L; Fernandes JF; Daudt LE; Grecco CS; Darrigo-Jr LG; Villela N; Nichele S; Gouveia R; Bouzas LF; Hamerschlak N; Vigorito AC; da Silva PM; da Silva PO; da Silva CC; de Souza Fernandez C; Flowers ME; Arcuri LJ
Pediatr Transplant; 2020 Nov; 24(7):e13789. PubMed ID: 32757316
[TBL] [Abstract][Full Text] [Related]
7. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?
Konuma T; Itonaga H; Ishiyama K; Doki N; Uchida N; Sawa M; Katayama Y; Tanaka M; Ueda Y; Onizuka M; Miyakoshi S; Ozawa Y; Fukuda T; Matsuoka KI; Tanaka J; Kimura T; Ichinohe T; Atsuta Y
Bone Marrow Transplant; 2023 Aug; 58(8):893-906. PubMed ID: 37156881
[TBL] [Abstract][Full Text] [Related]
8. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
10. Similar outcomes of allogeneic hematopoietic cell transplantation from unrelated donor and umbilical cord blood vs. sibling donor for pediatric acute myeloid leukemia: Multicenter experience in China.
Tang X; Chen J; Fang J; Sun X; Qin MQ; Li J; Zhu Y; Luan Z
Pediatr Transplant; 2015 Jun; 19(4):413-21. PubMed ID: 25903451
[TBL] [Abstract][Full Text] [Related]
11. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
[TBL] [Abstract][Full Text] [Related]
12. Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients.
Ke P; Bao XB; Hu XH; Zhuang J; Wu XJ; Liu YJ; He XF; Wu DP; Xue SL; Ma X
Bone Marrow Transplant; 2018 Feb; 53(2):162-168. PubMed ID: 29084206
[TBL] [Abstract][Full Text] [Related]
13. Current status of allogeneic hematopoietic cell transplantation for MDS.
Xu F; Deeg HJ
Curr Pharm Des; 2012; 18(22):3215-21. PubMed ID: 22571701
[TBL] [Abstract][Full Text] [Related]
14. Similar overall survival using sibling, unrelated donor, and cord blood grafts after reduced-intensity conditioning for older patients with acute myelogenous leukemia.
Peffault de Latour R; Brunstein CG; Porcher R; Chevallier P; Robin M; Warlick E; Xhaard A; Ustun C; Larghero J; Dhedin N; Mohty M; Socié G; Weisdorf D
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1355-60. PubMed ID: 23791622
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.
Pasquini MC; Zhang MJ; Medeiros BC; Armand P; Hu ZH; Nishihori T; Aljurf MD; Akpek G; Cahn JY; Cairo MS; Cerny J; Copelan EA; Deol A; Freytes CO; Gale RP; Ganguly S; George B; Gupta V; Hale GA; Kamble RT; Klumpp TR; Lazarus HM; Luger SM; Liesveld JL; Litzow MR; Marks DI; Martino R; Norkin M; Olsson RF; Oran B; Pawarode A; Pulsipher MA; Ramanathan M; Reshef R; Saad AA; Saber W; Savani BN; Schouten HC; Ringdén O; Tallman MS; Uy GL; Wood WA; Wirk B; Pérez WS; Batiwalla M; Weisdorf DJ
Biol Blood Marrow Transplant; 2016 Feb; 22(2):248-257. PubMed ID: 26327629
[TBL] [Abstract][Full Text] [Related]
16. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
17. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome.
Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
Bhatt VR; Steensma DP
J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.
Deeg HJ; Bartenstein M
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):31-41. PubMed ID: 22143157
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation.
Salit RB; Milano F; Delaney C
Biol Blood Marrow Transplant; 2016 Feb; 22(2):339-343. PubMed ID: 26485444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
